SEC filings and other documents

Discontinuation of TACTI-004 caused impairment, but strong cash and positive clinical data support future prospects.

First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity.

Net loss doubled on higher R&D, but cash position strengthened by Dr. Reddy's deal.

Secured A$30M upfront in a global licensing deal and reported robust clinical and cash progress.

Clinical trials progress and robust cash position extend funding runway to end of CY2026.

Major clinical progress, strong finances, and all resolutions passed amid sector challenges.

Phase III lung cancer trial progresses on schedule, with key data and pipeline updates expected soon.

Advanced Phase III trials and strong cash position support continued clinical progress.

Clinical pipeline advances and solid cash reserves support operations through CY2026.

Strong clinical pipeline and financial position drive global phase III and expansion in oncology.

Efti delivers strong efficacy and safety in NSCLC, positioning Immutep for major market impact.

Clinical milestones achieved and robust cash reserves position Immutep for continued progress.

Advanced to Phase III trials, boosted revenue 77%, and secured funding through CY2026.

Advanced to Phase III, Immutep posts robust clinical results and strong cash position.

Eftilagimod alpha plus Keytruda delivers durable responses in hard-to-treat cancer populations.

AGM showcased clinical, financial, and regulatory progress, with all resolutions passed.

Advanced clinical pipeline, secured major funding, and strengthened partnerships for late-stage trials.

Efti delivers strong efficacy in NSCLC and HNSCC, with pivotal Phase III and autoimmune trials underway.

Phase III NSCLC trial with Merck and strong head and neck cancer data drive near-term catalysts.

Efti plus KEYTRUDA delivers exceptional chemo-free efficacy in CPS < 1 HNSCC patients.